Table 6.
The level of resistance to first-line antiretroviral drugs for individuals
| Variables | High-level n (%) | Intermediate level n (%) | Low-level n (%) |
|---|---|---|---|
| NRTIs | |||
| 3TC | 40 (93.0) | 1 (2.3) | 2 (4.7) |
| ABC | 13 (30.2) | 5 (11.6) | 25 (58.2) |
| AZT | 4 (9.3) | 21 (48.8) | 18 (41.9) |
| d4T | 18 (41.9) | 15 (34.9) | 10 (23.2) |
| FTC | 40 (93.0) | 1 (2.3) | 2 (4.7) |
| ddI | 15 (34.9) | 3 (7.0) | 25 (58.1) |
| TDF | 11 (25.6) | 2 (4.7) | 30 (69.7) |
| NNRTIs | |||
| EFV | 24 (55.8) | 16 (37.2) | 3 (7.0) |
| ETR | 2 (4.7) | 18 (41.8) | 23 (53.5) |
| NVP | 41 (95.3) | 0 (0.0) | 2 (4.7) |
| PIs | |||
| ATV | 0 (0.0) | 0 (0.0) | 43 (100.0) |
| DRV | 0 (0.0) | 0 (0.0) | 43 (100.0) |
| FPV | 0 (0.0) | 0 (0.0) | 43 (100.0) |
| IDV | 0 (0.0) | 0 (0.0) | 43 (100.0) |
| LPV | 0 (0.0) | 0 (0.0) | 43 (100.0) |
| NFV | 0 (0.0) | 0 (0.0) | 43 (100.0) |
| SQV | 0 (0.0) | 1 (2.3) | 42 (97.7) |
| TPV | 0 (0.0) | 0 (0.0) | 43 (100.0) |
Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; ddI, didanosine; TDF, tenofovir disoproxil fumarate; NNRTI, non-nucleoside reverse transcriptase inhibitor; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; PI, protease inhibitor; ATV, atazanavir; DRV, darunavir; FPV, fosamprenavir; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; SQV, saquinavir; TPV, tipranavir.